Searched for
GILEAD PHARMA
Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billionGilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% to the stock's last close. Kite Pharma, a unit ?...- Gilead won't launch its Covid drug in JulyGilead has issued licences to nine generic drug companies to make and sell remdesivir. Six of the companies are Indian - Hetero, Cipla, Dr ...
- Dr Reddy’s inks licensing pact with Gilead for Remdesivir to treat Covid-19The Hyderabad headquartered drug maker will obtain technology transfer from Gilead for manufacturing of the drug wherein the Indian firm wo...
- Maharashtra's plan to buy drug from Bangladesh irks local companiesIndian firms said that the Bangladeshi company with which Mantralaya is in talks has neither the import licence, nor a manufacturing licenc...
- BDR in pact to make Gilead drug for CiplaIn late May, BDR had sought the approval of India’s drug regulator to make and sell remdesivir in India without entering into an arrangemen...
- Will Gilead’s Covid-19 drug lift sustain for Jubilant Life, Cipla?Use of remdesivir is said to reduce hospital stay by 31 per cent to 11 days from 15 days.
- More companies in talks for Remdesivir licenceThis week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received ...
- Government's patent grant to Gilead challenged in Delhi High CourtGilead has claimed existing public knowledge as its own and its patent on sofosbuvir, the base compound in its HepC drug Sovaldi, is "unmer...
- Natco gets DCGI nod to launch hepatitis C drug in IndiaNatco Pharma has received approval from the Drugs Controller General of India (DCGI) to launch generic version of hepatitis C treatment dru...
- Natco settles patent suit with Gilead, others over TamifluNatco Pharma and its partner Alvogen today said they have settled patent infringement suit with Gilead Sciences Inc and others over Tamiflu.
- Gilead adds ten new countries for Sovaldi access programmeGilead said that it has also updated the pricing structure for drugs that it will be selling through its partner.
- Dr Reddy's to launch Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- Zydus Cadila launches Gilead's Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- Patent row no hurdle for Gilead Pharma’s Sovaldi launchGilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India...
- Strides Arcolab inks pact with Gilead Sciences for HIV drugStrides has entered into a licensing agreement with Gilead to manufacture and distribute latter's low-cost TAF used for HIV treatment in de...
- Gilead to challenge hepatitis C drug patent rejection decision"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.
- Cipla on firm ground in patent challengeIn what could strengthen Cipla's patent challenge against global major Gilead Science's patent application for its key HIV drug, Viread, th...
- Anti-AIDS blitz sees pharma firms locked in ugly battleIt has now emerged that Aids Healthcare Foundation (AHF), the US-based NGO that accused Cipla of over pricing anti-AIDS drug, Viraday, in I...
- Cipla lends support to anti-patent driveDomestic pharma major Cipla is opposing US-based biotech major Gilead Sciences’ patent application in India for anti-AIDS drug Viread.
- Gilead’s anti-AIDS drug to cost $1 a day hereViread, the largest selling anti-HIV/AIDS drug in the United States, will be available to patients in India at a special price equivalent o...
Load More
